Pharmaceuticals 11 February 2026

Vanda Pharmaceuticals stock jumps premarket after FDA clears Bysanti — what to watch at the open

Shares of Vanda Pharmaceuticals jumped roughly 33% to $7.68 in premarket trading Monday, following a late FDA approval announced Friday that triggered a surge after hours.

23 February 2026

NASDAQ:VNDA·Pharmaceuticals·Stock Market

Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears

Johnson & Johnson shares closed down 1.8% on Friday at $242.49, leaving the JNJ stock price softer into the weekend.

22 February 2026

Dividend Investing·NYSE:JNJ·Pharmaceuticals·Stock Market

Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson is weighing a sale of its DePuy Synthes orthopedics division that could fetch more than $20 billion, according to a source familiar with the situation, speaking to Reuters on Thursday. The company hasn’t commented yet. This potential sale marks a pivot from J&J’s previously outlined plan to spin off DePuy Synthes over the next 18 to 24 months. CFO Joe Wolk previously indicated no major updates would come before mid-2026. DePuy pulled in $9.3 billion in sales for 2025 and has faced thousands of hip implant lawsuits, Reuters noted.

21 February 2026

NYSE:JNJ·Pharmaceuticals·Stock Market

GSK share price slips as Arexvy RSV data lands and stock goes ex-dividend

GSK slipped 0.39% to 2,259 pence by 0901 GMT in early London trading, following new real-world data on its RSV shot Arexvy and the stock going ex-dividend. The shares had kicked off at 2,252 pence, just a day after touching a 52-week peak of 2,282 pence; they’ve climbed roughly 57% in the last year.

19 February 2026

Dividends·Earnings Reports·LSE:GSK·Pharmaceuticals·Stock Market

Why CSL’s share price is moving: Lilly clazakizumab deal, buyback pace and the next dividend date

CSL Limited finished Thursday’s session at A$154.19, up 0.95%. Shares bounced between A$152.13 and A$154.45 during the day. While that makes two days in positive territory, the stock is still roughly 15% off its early-February highs.

19 February 2026

ASX:CSL.AX·Dividends·Pharmaceuticals·Stock Market

Why GSK stock is moving today: Exdensur EU nod and a fresh buyback

GSK picked up roughly 1% on Wednesday, after the company announced European Commission approval for its Exdensur treatment—used for asthma and nasal polyps—and kicked off another round of share buybacks. Shares traded at 2,263 pence, up 1.1%.

18 February 2026

EU Regulations·LSE:GSK.L·Pharmaceuticals

CSL stock price ends higher after Eli Lilly clazakizumab deal, with buyback in the background

CSL Ltd jumped up to 2.1% on Wednesday after the Australian biotech signed a licensing agreement with Eli Lilly for clazakizumab, an investigational antibody currently in trials for end-stage kidney disease.

18 February 2026

ASX:CSL·Pharmaceuticals·Stock Market

Eli Lilly stock in focus as Retevmo lung cancer trial meets endpoint, with trading back Tuesday

Eli Lilly and Company turned in upbeat topline data from a pivotal trial of its cancer therapy Retevmo, teeing up a new challenge for the stock as U.S. markets get back to action Tuesday after the holiday.

16 February 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Johnson & Johnson stock faces Tuesday test after fresh talc verdict as dividend date nears

Johnson & Johnson faces renewed pressure from talc lawsuits as the stock returns Tuesday, following a Pennsylvania jury’s verdict holding the company responsible in the most recent baby powder cancer case.

16 February 2026

Dividends·NYSE:JNJ·Pharmaceuticals·Stock Market

AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie Inc finished Friday at $231.50, up 1.8%. The stock moved between $227.33 and $234.69 over the session.

15 February 2026

NYSE:ABBV·Pharmaceuticals·Stock Market

Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

The Health Care Select Sector SPDR Fund ended Friday up about 1.1% at $157.67, as Dexcom jumped 7.6% and Moderna gained 5.3% after earnings updates.

15 February 2026

NASDAQ:DXCM·NASDAQ:MRNA·Pharmaceuticals

Eli Lilly stock price: $1.5 billion pill inventory puts April 10 FDA decision in spotlight

Eli Lilly and Company shares will be in the spotlight again when U.S. markets open Tuesday. The company revealed a $1.5 billion pre-launch inventory buildup for its oral weight-loss candidate, orforglipron. The stock last changed hands at $1,040.00, up roughly 0.2% from the previous finish. With markets closed Monday for Presidents Day, investors get one more day to process the update.

15 February 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Vertex stock jumps nearly 6% on Oppenheimer upgrade as traders size up new drug pipeline

Shares of Vertex Pharmaceuticals Inc jumped 5.7% to close at $491.47 on Friday, pushing the Boston biotech into focus ahead of the holiday-shortened week. Oppenheimer’s Jay Olson gave the stock an upgrade to “Outperform” and set a $540 target.

14 February 2026

NASDAQ:VRTX·Pharmaceuticals·Stock Market

Eli Lilly stock: LLY closes at $1,040 as $1.5 billion pill stockpile comes into focus

Eli Lilly finished Friday at $1,040, ticking up roughly 0.3%. Traders reacted to a fresh filing indicating the company’s been stockpiling its experimental weight-loss pill. Source: https://www.barrons.com/market-data/stocks/lly

14 February 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna jumped roughly 5% to $42.23 in late Friday trading. The vaccine maker managed to beat Wall Street’s revenue expectations and stuck with its 2026 growth targets, despite dealing with an FDA setback on its flu shot.

13 February 2026

Biotechnology·Earnings Reports·NASDAQ:MRNA·Pharmaceuticals·Stock Market

Merck stock pops on Deutsche Bank upgrade — what to watch ahead of ASCO GU

Merck & Co climbed 1.8% to $121.41 in Friday’s after-hours session, boosted by a Deutsche Bank upgrade to buy and a raised price target. Analyst James Shin argued, “We believe the market is currently undervaluing MRK … a clear path for MRK to navigate this transition.” Deutsche Bank projects that between the pipeline and recent acquisitions, Merck could tack on over $35 billion in risk-adjusted revenue by 2035.

13 February 2026

NYSE:MRK·Pharmaceuticals·Stock Market

Eli Lilly stock price climbs as $1.5 billion pill stockpile sharpens focus on FDA April decision

Eli Lilly and Company shares edged up 0.6% to $1,044.62 by midday, having traded between $1,034.69 and $1,063.68 earlier.

13 February 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focus

Eli Lilly and Company climbed almost 2% Thursday, pushing its rebound further as the company reported new regulatory progress for mirikizumab in China—a drug aimed at inflammatory bowel disease. By late morning, shares traded at $1,033.23, up 1.8%. The Health Care Select Sector SPDR Fund posted modest gains. Novo Nordisk’s U.S. shares, however, slipped.

12 February 2026

NYSE:LLY·Pharmaceuticals·Stock Market

GSK share price drops in early London trade as Arexvy China filing and insider sales set the tone

GSK slipped roughly 1.5% to 2,117 pence in early trading Thursday in London, pulling back after a robust run earlier this year. Shares had closed Wednesday at 2,153 pence.

12 February 2026

LSE:GSK.L·Pharmaceuticals·Stock Market

Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer slipped 0.3% to $27.52 ahead of the bell Wednesday, following a 2.1% gain Tuesday that took shares to $27.61. The stock hit $27.73 during the session, with trading volume reaching roughly 43.6 million shares.

11 February 2026

NYSE:PFE·Pfizer·Pharmaceuticals·Stock Market

Pharmaceuticals 11 February 2026 - 23 February 2026